EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial

Research output: Contribution to journalLetterAcademicpeer-review

38 Citations (Scopus)
Original languageEnglish
Pages (from-to)472-474
Number of pages3
JournalAnnals of the Rheumatic Diseases
Volume73
Issue number2
DOIs
Publication statusPublished - Feb-2014

Keywords

  • Antibodies, Monoclonal, Murine-Derived
  • Double-Blind Method
  • Humans
  • Immunologic Factors
  • Severity of Illness Index
  • Sjogren's Syndrome
  • Treatment Outcome
  • RESPONSIVENESS

Cite this